Literature DB >> 18501939

Tear gasses CN, CR, and CS are potent activators of the human TRPA1 receptor.

Bert Brône1, Pieter J Peeters, Roger Marrannes, Marc Mercken, Ronny Nuydens, Theo Meert, Harrie J M Gijsen.   

Abstract

The TRPA1 channel is activated by a number of pungent chemicals, such as allylisothiocyanate, present in mustard oil and thiosulfinates present in garlic. Most of the known activating compounds contain reactive, electrophilic chemical groups, reacting with cysteine residues in the active site of the TRPA1 channel. This covalent modification results in activation of the channel and has been shown to be reversible for several ligands. Commonly used tear gasses CN, CR and CS are also pungent chemicals, and in this study we show that they are extremely potent and selective activators of the human TRPA1 receptor. To our knowledge, these are the most potent TRPA1 agonists known to date. The identification of the molecular target for these tear gasses may open up possibilities to alleviate the effects of tear gasses via treatment with TRPA1 antagonists. In addition these results may contribute to the basic knowledge of the TRPA1 channel that is gaining importance as a pharmacological target.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18501939     DOI: 10.1016/j.taap.2008.04.005

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  27 in total

Review 1.  Sensory detection and responses to toxic gases: mechanisms, health effects, and countermeasures.

Authors:  Bret F Bessac; Sven-Eric Jordt
Journal:  Proc Am Thorac Soc       Date:  2010-07

Review 2.  The TRPA1 channel in migraine mechanism and treatment.

Authors:  S Benemei; C Fusi; Gabriela Trevisan; Pierangelo Geppetti
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

3.  The combined use of systemic analgesic/anti-inflammatory drugs and a bioactive topical desensitizer for reduced in-office bleaching sensitivity without jeopardizing the hydrogen peroxide efficacy: a randomized, triple blinded, split-mouth clinical trial.

Authors:  Isabela Dantas Torres de Araújo; Kaiza de Sousa Santos; Thauan Victor Oliveira das Neves Peixoto; Moan Jéfter Fernandes Costa; Isauremi Vieira de Assunção; Boniek Castillo Dutra Borges
Journal:  Clin Oral Investig       Date:  2021-04-22       Impact factor: 3.573

Review 4.  Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field.

Authors:  Magdalene M Moran; Arpad Szallasi
Journal:  Br J Pharmacol       Date:  2017-11-06       Impact factor: 8.739

5.  TRPA1 and CGRP antagonists counteract vesicant-induced skin injury and inflammation.

Authors:  Satyanarayana Achanta; Narendranath Reddy Chintagari; Marian Brackmann; Shrilatha Balakrishna; Sven-Eric Jordt
Journal:  Toxicol Lett       Date:  2018-03-10       Impact factor: 4.372

Review 6.  Regulation of Pain and Itch by TRP Channels.

Authors:  Carlene Moore; Rupali Gupta; Sven-Eric Jordt; Yong Chen; Wolfgang B Liedtke
Journal:  Neurosci Bull       Date:  2017-12-27       Impact factor: 5.203

Review 7.  Breathtaking TRP channels: TRPA1 and TRPV1 in airway chemosensation and reflex control.

Authors:  Bret F Bessac; Sven-Eric Jordt
Journal:  Physiology (Bethesda)       Date:  2008-12

8.  Transient receptor potential ankyrin 1 antagonists block the noxious effects of toxic industrial isocyanates and tear gases.

Authors:  Bret F Bessac; Michael Sivula; Christian A von Hehn; Ana I Caceres; Jasmine Escalera; Sven-Eric Jordt
Journal:  FASEB J       Date:  2008-11-26       Impact factor: 5.191

9.  TRPA1 agonists evoke coughing in guinea pig and human volunteers.

Authors:  Mark A Birrell; Maria G Belvisi; Megan Grace; Laura Sadofsky; Shoaib Faruqi; David J Hele; Sarah A Maher; Véronique Freund-Michel; Alyn H Morice
Journal:  Am J Respir Crit Care Med       Date:  2009-09-03       Impact factor: 21.405

Review 10.  TRP channel antagonists as potential antitussives.

Authors:  Megan S Grace; Eric Dubuis; Mark A Birrell; Maria G Belvisi
Journal:  Lung       Date:  2011-10-02       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.